Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis

References

1. 1.↵
   1. Sergentanis TN,
   2. Zagouri F,
   3. Tsilimidos G,
   4. et al

   . Risk factors for multiple myeloma: a systematic review of meta-analyses. Clin Lymphoma Myeloma Leuk 2015;15:563–77.e1–3.
2. 2.↵
   1. Landgren O,
   2. Waxman AJ

   . Multiple myeloma precursor disease. JAMA 2010;304:2397–404.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Kyle RA,
   2. Durie BGM,
   3. Rajkumar SV,
   4. et al

   . Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Rajkumar SV,
   2. Dimopoulos MA,
   3. Palumbo A,
   4. et al

   . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Durie BG,
   2. Salmon SE

   . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842–54.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Greipp PR,
   2. San Miguel J,
   3. Durie BG,
   4. et al

   . International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Bianchi G,
   2. Kyle RA,
   3. Colby CL,
   4. et al

   . Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood 2010;116:2019–25; quiz 2197.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Mateos M-V,
   2. Hernández M-T,
   3. Giraldo P,
   4. et al

   . Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013;369:438–47.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Deyo RA,
   2. Rainville J,
   3. Kent DL

   . What can the history and physical examination tell us about low back pain? JAMA 1992;268:760–5.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Kyle RA,
    2. Rajkumar SV

    . Multiple myeloma. N Engl J Med 2004;351:1860–73.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Dobson CM,
    2. Russell AJ,
    3. Rubin GP

    . Patient delay in cancer diagnosis: what do we really mean and can we be more specific? BMC Health Serv Res 2014;14:387.

    OpenUrl
12. 12.↵
    National Patient Safety Agency, Royal College of General Practitioners. Delayed diagnosis of cancer: thematic review. Data report, ref. no. 0968. London: NHS England; 2010. Available from: http://www.nrls.npsa.nhs.uk/resources/?EntryId45=69894. Accessed September 28, 2016.
13. 13.↵
    1. Hill A,
    2. Elkin K,
    3. Davidson N

    . Delayed diagnosis of cancer in primary care: what do our complaints tell us? New Zealand: Health and Disability Commissioner; 2015. Available from: http://www.hdc.org.nz/publications/other-publications-from-hdc/articles/2015/delayed-diagnosis-of-cancer-in-primary-care-what-do-our-complaints-tell-us. Accessed September 28, 2016.
14. 14.↵
    1. Green LA,
    2. Fryer GE,
    3. Yawn BP,
    4. Lanier D,
    5. Dovey SM

    . The ecology of medical care revisited. N Engl J Med 2001;344:2021–5.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Jarvik JG,
    2. Deyo RA

    . Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med 2002;137:586–97.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Kariyawasan CC,
    2. Hughes DA,
    3. Jayatillake MM,
    4. Mehta AB

    . Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007;100:635–40.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Friese CR,
    2. Abel GA,
    3. Magazu LS,
    4. Neville BA,
    5. Richardson LC,
    6. Earle CC

    . Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma 2009;50:392–400.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. van den Hoogen HM,
    2. Koes BW,
    3. van Eijk JT,
    4. Bouter LM

    . On the accuracy of history, physical examination, and erythrocyte sedimentation rate in diagnosing low back pain in general practice. A criteria-based review of the literature. Spine 1995;20:318–27.

    OpenUrlPubMedWeb of Science
19. 19.↵
    1. Dispenzieri A,
    2. Kyle R,
    3. Merlini G,
    4. et al

    . International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Dimopoulos M,
    2. Kyle R,
    3. Fermand J-P,
    4. et al

    . Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701–5.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Espersen F,
    2. Birgens HS,
    3. Hertz JB,
    4. Drivsholm A

    . Current patterns of bacterial infection in myelomatosis. Scand J Infect Dis 1984;16:169–73.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Kyle RA,
    2. Gertz MA,
    3. Witzig TE,
    4. et al

    . Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Fechtner K,
    2. Hillengass J,
    3. Delorme S,
    4. et al

    . Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology 2010;257:195–204.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Rajkumar SV,
    2. Kyle RA

    . Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005;80:1371–82.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Abel GA,
    2. Friese CR,
    3. Neville BA,
    4. et al

    . Referrals for suspected hematologic malignancy: a survey of primary care physicians. Am J Hematol 2012;87:634–6.

    OpenUrlCrossRefPubMed